CTLA4 and hepatocellular carcinoma: To identify the signatures of high immune risk, immune escape and better response to immunotherapies (anti-PD1/CTLA4) in HCC, we selected cluster1 and cluster3 as the phenotypes for comparison, because of the variances in clinical, molecular and genomic characteristics of cluster1 and cluster3 as described above.